Corestemchemon Net Debt / EBITDA
The Net Debt to EBITDA of Corestemchemon (166480.KQ) as of Oct 9, 2026 is -0.50. In the previous year, Net Debt to EBITDA was -1.54 — a change of -67.91% (higher).
Get this data via API
Financial Data API
Net Debt / EBITDA
-0.50
YoY
-67.91%
Last updated:
The Corestemchemon Net Debt / EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Net Debt / EBITDA | YoY |
|---|---|---|
| -0.50 | -67.91% | |
| -1.54 | +7.65% | |
| -1.43 | -194.97% | |
| 1.51 | -63.70% | |
| 4.16 | -63.96% | |
| 11.55 | +70.59% | |
| 6.77 | -37.24% | |
| 10.79 | +28.17% | |
| 8.42 | -78.43% | |
| 39.01 | -256.27% | |
| -24.96 | +401.69% | |
| -4.98 | +79.61% | |
| -2.77 | +115.81% | |
| -1.28 | — |
Corestemchemon Stock analysis
Frequently Asked Questions about Corestemchemon stock
Net Debt to EBITDA of Corestemchemon is -0.50 in 2025.
Net Debt to EBITDA of Corestemchemon changed from -1.54 to -0.50, representing a -67.91% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Net Debt to EBITDA Corestemchemon since 2006 – with annual values, charts, and detailed analysis.
Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Corestemchemon with sector peers and the industry average to assess whether it is attractive.
Leverage — Corestemchemon
All Key Metrics — Corestemchemon
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth